About Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals is a company based in Florence (United States) founded in 2001 was acquired by VersaPharm in August 2012.. Xanodyne Pharmaceuticals has raised $175.78 million across 4 funding rounds from investors including AIG, Skandia and Union Springs Healthcare. The company has 6 employees as of December 31, 2022. Xanodyne Pharmaceuticals has completed 1 acquisition, including Integrity Pharmaceuticals. Xanodyne Pharmaceuticals operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Florence, United States
- Employees 6 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Xanodyne Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$175.78 M (USD)
in 4 rounds
-
Latest Funding Round
$87.78 M (USD), Series D
Oct 30, 2009
-
Investors
AIG
& 11 more
-
Employee Count
6
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
VersaPharm
(Aug 01, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals has successfully raised a total of $175.78M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $87.78 million completed in October 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $87.8M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2009 | Amount | Series D - Xanodyne Pharmaceuticals | Valuation | MPM Capital , AIG Investments |
|
| Oct, 2009 | Amount | Series D - Xanodyne Pharmaceuticals | Valuation |
investors |
|
| Jun, 2009 | Amount | Series D - Xanodyne Pharmaceuticals | Valuation | MPM Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include AIG, Skandia and Union Springs Healthcare. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Late-stage investments in US tech companies are targeted.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Integrity Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufactures high-quality OB/GYN, urology products, and nutritional supplements.
|
1998 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Xanodyne Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xanodyne Pharmaceuticals Comparisons
Competitors of Xanodyne Pharmaceuticals
Xanodyne Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xanodyne Pharmaceuticals
Frequently Asked Questions about Xanodyne Pharmaceuticals
When was Xanodyne Pharmaceuticals founded?
Xanodyne Pharmaceuticals was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Where is Xanodyne Pharmaceuticals located?
Xanodyne Pharmaceuticals is headquartered in Florence, United States.
Is Xanodyne Pharmaceuticals a funded company?
Xanodyne Pharmaceuticals is a funded company, having raised a total of $175.78M across 4 funding rounds to date. The company's 1st funding round was a Series D of $38M, raised on Oct 01, 2002.
How many employees does Xanodyne Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Xanodyne Pharmaceuticals is 6.
What does Xanodyne Pharmaceuticals do?
Xanodyne Pharmaceuticals (formerly known as Xanodyne Pharmacal) has developed drugs for womens health and pain management. The product pipeline includes Zipsor, for the treatment of mild to moderate acute pain (FDA approval); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) (phase III and NDA filing); and XP20B for the treatment of mild to moderate pain (phase III).
Who are the top competitors of Xanodyne Pharmaceuticals?
Xanodyne Pharmaceuticals's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
How many acquisitions has Xanodyne Pharmaceuticals made?
Xanodyne Pharmaceuticals has made 1 acquisition, including Integrity Pharmaceuticals.
Who are Xanodyne Pharmaceuticals's investors?
Xanodyne Pharmaceuticals has 12 investors. Key investors include AIG, Skandia, Union Springs Healthcare, VersaPharm, and Turmeric Acquisition Corp.